Document is current
Any future updates will be listed below
-
Authors
Mietzsch, Mario https://orcid.org/0000-0001-8957-3363
Hsi, Jane https://orcid.org/0000-0002-0076-4217
Nelson, Austin R.
Khandekar, Neeta
Huang, Ann-Maree
Smith, Nicholas JC https://orcid.org/0000-0003-2409-9239
Zachary, Jon
Potts, Lindsay https://orcid.org/0009-0006-8266-3941
Farrar, Michelle A. https://orcid.org/0000-0002-4472-0902
Chipman, Paul https://orcid.org/0000-0003-3652-4087
Ghanem, Mohammad
Alexander, Ian E. https://orcid.org/0000-0002-6213-5627
Logan, Grant J.
Huiskonen, Juha T. https://orcid.org/0000-0002-0348-7323
McKenna, Robert https://orcid.org/0000-0002-2792-935X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (GM082946, GM082946)
Department of Health | National Health and Medical Research Council (APP1194940, APP2004320, APP2029992, APP2004320, APP2029992)
Rebecca L. Cooper Medical Research Foundation (PG2019449)
Academy of Finland (348021)
Research Council of Finland
- License Information
-
More Information
Article History
Received: 15 April 2024
Accepted: 11 April 2025
First Online: 19 April 2025
Competing interests
: IAE and GJL are in advanced discussion with a biotechnology company regarding the commercial manufacture and distribution of the monoclonal antibodies (mAbs) described in this manuscript. These negotiations may result in financial compensation for IAE and GJL and their affiliated organizations. JTH is co-founder and CEO of Nanometria, a limited liability company. The University of Florida Research Foundation, Inc. has filed a patent application (PCT/US2024/015006 []) on behalf of MM, JH, ARN, and RM based on the capsid variants described in this study. The remaining authors declare no competing interests.
